首页> 外文期刊>Human vaccines & immunotherapeutics. >Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice
【24h】

Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice

机译:通过共同施用可溶性PD-1和Tim-3作为小鼠的分子佐剂,增强SIV特异性细胞介导的免疫反应

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The development of an effective T cell based HIV vaccine would need to elicit cell mediated immune responses with superior magnitude, breadth, and quality. Since blocking the interactions between inhibitory receptors with their associated ligands using soluble PD-1 (sPD-1) and soluble Tim-3 (sTim-3) have been shown to reverse T cell exhaustion and enhance cell mediated immune responses, we tested if co-administration of sPD-1 and sTim-3 with an adenovirus vectored SIV vaccine (rAd5-SIV) can enhance cell mediated immune responses. The frequency of SIV antigen specific IFN-gamma spot-forming cells and the secretion of IFN-gamma and TNF-alpha by splenocytes from rAd5-SIV immunized mice were significantly increased when stimulated ex vivo with SIV peptides in the presence of sPD-1 or sTim-3 or both sPD-1 and sTim-3. The magnitude of cell mediated immune responses elicited by rAd5-SIV was enhanced by co-administration of sPD-1 and sTim-3. Co-administration of both sPD-1 and sTim-3 induced higher frequency of SIV antigen specific IFN-gamma(+) spot-forming cells to poorly immunogenic Vif and Tat. The percentage of cell mediated responses for each SIV antigen became more balanced, with reduction to Gag but induction to non-structural proteins. Furthermore, co-injection of rAd5-sPD1 and rAd5-sTim3 with rAd5-SIV in mice enhanced T cell proliferation capability and generated more antigen specific IFN-gamma(+) CD4(+) and CD8(+) T cells. Our study provided a new approach to enhance vaccine induced cell mediated immune responses, which may be applicable to improve the efficacy of vaccines against SIV/HIV.
机译:有效的基于T细胞的HIV疫苗的开发将需要引起细胞介导的免疫反应,具有更高的幅度,广度和质量。由于使用可溶性PD-1(sPD-1)和可溶性Tim-3(sTim-3)阻断抑制性受体与其相关配体之间的相互作用已显示可逆转T细胞衰竭并增强细胞介导的免疫反应,因此我们测试了是否腺病毒载体SIV疫苗(rAd5-SIV)的sPD-1和sTim-3的联合给药可增强细胞介导的免疫反应。当在存在sPD-1或sPD-1或sTim-3或sPD-1和sTim-3两者。通过同时施用sPD-1和sTim-3,可以增强rAd5-SIV引起的细胞介导的免疫反应的强度。 sPD-1和sTim-3的共同给药可诱导免疫原性差的Vif和Tat更高频率的SIV抗原特异性IFN-γ(+)点形成细胞。每个SIV抗原的细胞介导应答百分比变得更加平衡,减少了Gag,但诱导了非结构蛋白。此外,在小鼠中共注射rAd5-sPD1和rAd5-sTim3与rAd5-SIV可增强T细胞增殖能力,并产生更多的抗原特异性IFN-γ(CD)CD4(+)和CD8(+)T细胞。我们的研究提供了一种增强疫苗诱导的细胞介导的免疫反应的新方法,该方法可能适用于提高针对SIV / HIV的疫苗的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号